CVKD

Cadrenal Therapeutics, Inc. (CVKD) - 10-K Summary

Business Context and Reporting Period

Reporting Period: Fiscal year ended December 31, 2025.

Company Overview: Cadrenal Therapeutics is a late-stage biopharmaceutical company focused on novel therapies for immune and thrombotic conditions. In December 2025, the company pivoted its primary strategic focus to the development of CAD-1005, a first-in-class selective 12-LOX inhibitor for Heparin-Induced Thrombocytopenia (HIT), following the acquisition of assets from Veralox Therapeutics. The pipeline also includes tecarfarin (an oral Vitamin K antagonist) and frunexian (an IV Factor XIa inhibitor).

Key Milestone: On March 26, 2026, the company completed its End-of-Phase 2 (EOP2) meeting with the FDA, clarifying a potential registrational path for a planned Phase 3 pivotal trial of CAD-1005.

Key Financial Metrics

Debt and Liquidity: The company has no long-term debt. As of December 31, 2025, total current liabilities were $1.6 million. The company raised approximately $6.6 million in net proceeds from financing activities in 2025, including a registered direct offering and sales under its At-The-Market (ATM) facility.

Material Changes vs. Prior Period

• Strategic Pivot: Acquired the 12-LOX platform (CAD-1005) from Veralox in December 2025, shifting focus from tecarfarin to CAD-1005 as the lead asset.
• Asset Acquisitions: Acquired assets from eXIthera (frunexian) in September 2025 and Veralox (CAD-1005) in December 2025. Costs associated with these acquisitions were expensed as in-process research and development (IPR&D).
• Expense Growth: General and Administrative (G&A) expenses increased by 39% ($2.6 million) primarily due to public company costs, stock-based compensation, and consulting fees. R&D expenses remained relatively flat, decreasing slightly by 2%.
• Cash Burn: Cash reserves decreased by approximately $6.0 million during the year, reflecting a burn rate of roughly $1.0 million per month.

Guidance, Outlook, and Risks

Outlook: Management expects to continue incurring significant operating losses. The company believes existing cash resources are insufficient to fund operations for the next 12 months. Additional financing is required to commence the planned Phase 3 trial for CAD-1005.

Going Concern: The independent auditor has issued an opinion with an explanatory paragraph regarding substantial doubt about the company's ability to continue as a going concern for one year following the issuance of the financial statements.

Key Risks:

• Capital Needs: Failure to secure additional funding could force the company to delay or cease clinical trials.
• Clinical Uncertainty: The Phase 2 trial for CAD-1005 did not meet its primary endpoint (platelet count recovery rate), though it showed a numerical reduction in thrombotic events. The Phase 3 trial design is subject to FDA review.
• Intellectual Property: Patents for tecarfarin expired in 2024/2025. The company relies on a license agreement with Old Dominion University for CAD-1005, which includes contingent milestone payments and royalties.
• Regulatory: Potential delays due to FDA staffing issues or government shutdowns.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $4.0 million cash balance against the projected costs of the upcoming Phase 3 trial and general operations.
• Financing Plans: Confirm the status of any pending equity or debt financing required to bridge the liquidity gap.
• Phase 3 Protocol: Review the final FDA meeting minutes from the March 26, 2026 EOP2 meeting to understand the specific requirements for the pivotal trial.
• License Obligations: Assess the financial impact of the contingent milestone payments (up to $15 million) and royalties owed to Veralox and Old Dominion University upon regulatory approval.
• Patent Status: Confirm the timeline for new patent filings for CAD-1005 to ensure market exclusivity, given the expiration of tecarfarin patents.